AbbVie, a leading biopharmaceutical company, has entered the obesity field through a partnership with Gubra A/S. The agreement allows AbbVie to develop and commercialize GUB014295, an amylin peptide that could potentially treat obesity.
GUB014295 is currently in Phase 1 clinical trials and has shown promising results in activating signals to the brain that result in appetite suppression and reduced food intake. Obesity affects nearly 900 million adults globally, making it a significant global health concern.
Under the terms of the agreement, AbbVie will lead development and commercialization activities globally, with Gubra receiving $350 million upfront payment and up to $1.875 billion in potential milestone payments. The partnership is expected to accelerate the development of GUB014295 and create new opportunities for both companies.
“This partnership marks our entry into the obesity field, offering a compelling opportunity to address patient needs while fostering long-term growth,” said Robert A. Michael, AbbVie’s CEO. “We look forward to advancing the development of the GUB014295 program with Gubra.”
The collaboration between AbbVie and Gubra is seen as a positive move in addressing the growing global health issue of obesity. With this partnership, both companies aim to make a significant impact on people’s lives across several key therapeutic areas.
For more information about AbbVie, please visit www.abbvie.com, or follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Source: https://www.prnewswire.com/news-releases/abbvie-and-gubra-announce-license-agreement-to-develop-an-amylin-analog-for-the-treatment-of-obesity-302389687.html